GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Effective Interest Rate on Debt %

Skye Bioscience (Skye Bioscience) Effective Interest Rate on Debt % : 36.99% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Skye Bioscience's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $1.75 Mil. Skye Bioscience's average total debt for the quarter that ended in Mar. 2024 was $4.73 Mil. Therefore, Skye Bioscience's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 36.99%.


Skye Bioscience Effective Interest Rate on Debt % Historical Data

The historical data trend for Skye Bioscience's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience Effective Interest Rate on Debt % Chart

Skye Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 114.53 74.91 42.32 32.29 27.46

Skye Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.48 245.95 49.25 38.04 36.99

Competitive Comparison of Skye Bioscience's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Skye Bioscience's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Skye Bioscience's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Skye Bioscience's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Skye Bioscience's Effective Interest Rate on Debt % falls into.



Skye Bioscience Effective Interest Rate on Debt % Calculation

Skye Bioscience's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -0.906/( (1.983+4.615)/ 2 )
=-1  *  -0.906/3.299
=27.46 %

where

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.171 + 4.444
=4.615

Skye Bioscience's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  -1.748/( (4.615+4.836)/ 2 )
=-1  *  -1.748/4.7255
=36.99 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.171 + 4.444
=4.615

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.151 + 4.685
=4.836

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Skye Bioscience  (NAS:SKYE) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Skye Bioscience Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Skye Bioscience (Skye Bioscience) Business Description

Industry
Traded in Other Exchanges
N/A
Address
11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease.
Executives
Punit Dhillon director 5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
John D Diekman 10 percent owner C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Vii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Paul A. Grayson director 10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
5am Ventures Vii, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Ventures Iii, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
5am Ventures Ii Lp 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Deborah H. Charych director 1001 17TH ST, SAN FRANCISCO CA 94107